---
document_datetime: 2025-12-29 14:32:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ghryvelin.html
document_name: ghryvelin.html
version: success
processing_time: 0.1098258
conversion_datetime: 2025-12-30 02:14:27.827662
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ghryvelin (previously Macimorelin Aeterna Zentaris)

[RSS](/en/individual-human-medicine.xml/67166)

##### Authorised

This medicine is authorised for use in the European Union

macimorelin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ghryvelin (previously Macimorelin Aeterna Zentaris)](#news-on)
- [More information on Ghryvelin (previously Macimorelin Aeterna Zentaris)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ghryvelin (previously Macimorelin Aeterna Zentaris) is a medicine used to test the ability of the body to produce growth hormone. It is used by doctors to diagnose growth hormone deficiency, a condition where the patient does not have enough growth hormone. It is not used to treat patients with the condition.

Ghryvelin contains the active substance macimorelin.

Expand section

Collapse section

## How is Ghryvelin used?

Ghryvelin is available as granules that are dissolved in water and taken by mouth. The recommended dose is 0.5 mg per kg body weight which the patient should take once. The doctor then takes blood samples 45, 60 and 90 minutes later to see how much growth hormone the body has produced.

Ghryvelin can only be obtained with a prescription and its use must be supervised by a healthcare professional experienced in diagnosing growth hormone deficiency. For more information about using GHRYVELIN, see the package leaflet or contact your doctor or pharmacist.

## How does Ghryvelin work?

The active substance in Ghryvelin, macimorelin, stimulates the release of growth hormone into the blood by activating receptors (targets) found on cells in the pituitary gland, a gland located at the base of the brain. The level of growth hormone in the blood is then measured and indicates whether or not the body is able to produce growth hormone.

## What benefits of Ghryvelin have been shown in studies?

Ghryvelin was compared with another test commonly used to diagnose growth hormone deficiency, called insulin tolerance test (ITT), in one main study.

The study involved 166 adults who had either a high, intermediate or low likelihood of having growth hormone deficiency, or who were confirmed not to have growth hormone deficiency. Among them, 140 were tested with both Ghryvelin and ITT.

Overall, 94% of people who tested negative for growth hormone deficiency with ITT also tested negative with Ghryvelin; 74% of people who tested positive with ITT also tested positive with Ghryvelin. This means that, although Ghryvelin might not diagnose all cases of disease, it can help to confirm presence of the disease.

## What are the risks associated with Ghryvelin?

The most common side effects with Ghryvelin (which may affect up to 1 in 10 people) are a bitter or metallic taste, tiredness, headache, nausea (feeling sick), dizziness, diarrhoea and feeling hot. Ghryvelin may also cause a change in heart rhythm. Overall, the side effects were mostly mild and short-lasting, with no need for a specific treatment.

For the full list of side effects and restrictions with Ghryvelin, see the package leaflet.

## Why is Ghryvelin authorised in the EU?

Ghryvelin gave a similar number of negative test results for growth hormone deficiency as a comparator test; however, it gives fewer positive test results than the comparator. EMA considered that it is a priority to avoid over-diagnosis of adult growth hormone deficiency and that Ghryvelin helps confirm positive diagnosis and so avoid unnecessary treatment of patients with a false positive test result.

In terms of safety, the main concern was that the medicine may change heart rhythm. However this risk is considered small as patients take only one dose of the medicine and are supervised by their doctor. On the whole, Ghryvelin has fewer side effects than the comparator test, which temporarily lowers the level of sugar in the blood.

EMA therefore decided that Ghryvelin's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ghryvelin?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ghryvelin have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ghryvelin are continuously monitored. Side effects reported with Ghryvelin are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ghryvelin

Ghryvelin received a marketing authorisation valid throughout the EU on 11 January 2019.

Ghryvelin (previously Macimorelin Aeterna Zentaris) : EPAR - Medicine overview

Adopted

Reference Number: EMA/820056/2018

English (EN) (89.65 KB - PDF)

**First published:** 26/02/2019

[View](/en/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-920)

български (BG) (102.81 KB - PDF)

**First published:**

26/02/2019

[View](/bg/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_bg.pdf)

español (ES) (75.54 KB - PDF)

**First published:**

26/02/2019

[View](/es/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_es.pdf)

čeština (CS) (99.5 KB - PDF)

**First published:**

26/02/2019

[View](/cs/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_cs.pdf)

dansk (DA) (73.27 KB - PDF)

**First published:**

26/02/2019

[View](/da/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_da.pdf)

Deutsch (DE) (76.09 KB - PDF)

**First published:**

26/02/2019

[View](/de/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_de.pdf)

eesti keel (ET) (72.93 KB - PDF)

**First published:**

26/02/2019

[View](/et/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (103.66 KB - PDF)

**First published:**

26/02/2019

[View](/el/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_el.pdf)

français (FR) (75.86 KB - PDF)

**First published:**

26/02/2019

[View](/fr/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (93.37 KB - PDF)

**First published:**

26/02/2019

[View](/hr/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_hr.pdf)

italiano (IT) (74.97 KB - PDF)

**First published:**

26/02/2019

[View](/it/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (102.21 KB - PDF)

**First published:**

26/02/2019

[View](/lv/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (95.74 KB - PDF)

**First published:**

26/02/2019

[View](/lt/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_lt.pdf)

magyar (HU) (94.4 KB - PDF)

**First published:**

26/02/2019

[View](/hu/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_hu.pdf)

Malti (MT) (100.38 KB - PDF)

**First published:**

26/02/2019

[View](/mt/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (75.16 KB - PDF)

**First published:**

26/02/2019

[View](/nl/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_nl.pdf)

polski (PL) (99.24 KB - PDF)

**First published:**

26/02/2019

[View](/pl/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_pl.pdf)

português (PT) (75.48 KB - PDF)

**First published:**

26/02/2019

[View](/pt/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_pt.pdf)

română (RO) (103.07 KB - PDF)

**First published:**

26/02/2019

[View](/ro/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (97.8 KB - PDF)

**First published:**

26/02/2019

[View](/sk/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (91.12 KB - PDF)

**First published:**

26/02/2019

[View](/sl/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.37 KB - PDF)

**First published:**

26/02/2019

[View](/fi/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_fi.pdf)

svenska (SV) (75.04 KB - PDF)

**First published:**

26/02/2019

[View](/sv/documents/overview/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-medicine-overview_sv.pdf)

Ghryvelin (previously Macimorelin Aeterna Zentaris) : EPAR - Risk-management-plan summary

English (EN) (56.95 KB - PDF)

**First published:** 26/02/2019

[View](/en/documents/rmp-summary/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-risk-management-plan-summary_en.pdf)

## Product information

Ghryvelin : EPAR - Product information

Adopted

English (EN) (312.95 KB - PDF)

**First published:** 26/02/2019

**Last updated:** 13/05/2024

[View](/en/documents/product-information/ghryvelin-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-931)

български (BG) (374.66 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/bg/documents/product-information/ghryvelin-epar-product-information_bg.pdf)

español (ES) (241.85 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/es/documents/product-information/ghryvelin-epar-product-information_es.pdf)

čeština (CS) (372.79 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/cs/documents/product-information/ghryvelin-epar-product-information_cs.pdf)

dansk (DA) (288.94 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/da/documents/product-information/ghryvelin-epar-product-information_da.pdf)

Deutsch (DE) (306.87 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/de/documents/product-information/ghryvelin-epar-product-information_de.pdf)

eesti keel (ET) (324.52 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/et/documents/product-information/ghryvelin-epar-product-information_et.pdf)

ελληνικά (EL) (365.88 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/el/documents/product-information/ghryvelin-epar-product-information_el.pdf)

français (FR) (353.24 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/fr/documents/product-information/ghryvelin-epar-product-information_fr.pdf)

hrvatski (HR) (342.43 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/hr/documents/product-information/ghryvelin-epar-product-information_hr.pdf)

íslenska (IS) (279.94 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/is/documents/product-information/ghryvelin-epar-product-information_is.pdf)

italiano (IT) (336.34 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/it/documents/product-information/ghryvelin-epar-product-information_it.pdf)

latviešu valoda (LV) (351.11 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/lv/documents/product-information/ghryvelin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (347.81 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/lt/documents/product-information/ghryvelin-epar-product-information_lt.pdf)

magyar (HU) (352.67 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/hu/documents/product-information/ghryvelin-epar-product-information_hu.pdf)

Malti (MT) (374.92 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/mt/documents/product-information/ghryvelin-epar-product-information_mt.pdf)

Nederlands (NL) (249.36 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/nl/documents/product-information/ghryvelin-epar-product-information_nl.pdf)

norsk (NO) (283.13 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/no/documents/product-information/ghryvelin-epar-product-information_no.pdf)

polski (PL) (357.02 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/pl/documents/product-information/ghryvelin-epar-product-information_pl.pdf)

português (PT) (293.72 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/pt/documents/product-information/ghryvelin-epar-product-information_pt.pdf)

română (RO) (355.51 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/ro/documents/product-information/ghryvelin-epar-product-information_ro.pdf)

slovenčina (SK) (357.56 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/sk/documents/product-information/ghryvelin-epar-product-information_sk.pdf)

slovenščina (SL) (342.03 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/sl/documents/product-information/ghryvelin-epar-product-information_sl.pdf)

Suomi (FI) (281.57 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/fi/documents/product-information/ghryvelin-epar-product-information_fi.pdf)

svenska (SV) (295.86 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

13/05/2024

[View](/sv/documents/product-information/ghryvelin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0020 12/01/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ghryvelin (previously Macimorelin Aeterna Zentaris) : EPAR - All authorised presentations

English (EN) (51.13 KB - PDF)

**First published:** 26/02/2019

**Last updated:** 25/11/2021

[View](/en/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-309)

български (BG) (78.36 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/bg/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_bg.pdf)

español (ES) (70.54 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/es/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (77.23 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/cs/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (73.83 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/da/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (72.91 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/de/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (68.94 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/et/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.15 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/el/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_el.pdf)

français (FR) (71.48 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/fr/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (71.63 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/hr/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (73.02 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/is/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (69.84 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/it/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.77 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/lv/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (71.31 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/lt/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (75.26 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/hu/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (71.54 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/mt/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (66.61 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/nl/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (68.99 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/no/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_no.pdf)

polski (PL) (70.11 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/pl/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_pl.pdf)

português (PT) (68.87 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/pt/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_pt.pdf)

română (RO) (70.07 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/ro/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (72.34 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/sk/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (69.63 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/sl/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (68.55 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/fi/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (67.48 KB - PDF)

**First published:**

26/02/2019

**Last updated:**

25/11/2021

[View](/sv/documents/all-authorised-presentations/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ghryvelin (previously Macimorelin Aeterna Zentaris) Active substance macimorelin acetate International non-proprietary name (INN) or common name macimorelin Therapeutic area (MeSH) Diagnostic Techniques, Endocrine Anatomical therapeutic chemical (ATC) code V04CD06

### Pharmacotherapeutic group

macimorelin

### Therapeutic indication

This medicinal product is for diagnostic use only. GHRYVELIN is indicated for the diagnosis of growth hormone deficiency (GHD) in adults.

## Authorisation details

EMA product number EMEA/H/C/004660

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Atnahs Pharma Netherlands B.V.

Copenhagen Towers,

Opinion adopted 15/11/2018 Marketing authorisation issued 11/01/2019 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ghryvelin (previously Macimorelin Aeterna Zentaris) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (172.25 KB - PDF)

**First published:** 25/11/2021

**Last updated:** 13/05/2024

[View](/en/documents/procedural-steps-after/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ghryvelin (previously Macimorelin Aeterna Zentaris)-H-C-4660-P46-004 : EPAR - Assessment report

Adopted

Reference Number: EMA/569390/2020

English (EN) (506.1 KB - PDF)

**First published:** 04/11/2020

[View](/en/documents/variation-report/ghryvelin-previously-macimorelin-aeterna-zentaris-h-c-4660-p46-004-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Ghryvelin (previously Macimorelin Aeterna Zentaris) : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/845216/2018

English (EN) (2.21 MB - PDF)

**First published:** 26/02/2019

[View](/en/documents/assessment-report/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Macimorelin Aeterna Zentaris

Adopted

Reference Number: EMA/CHMP/777751/2018

English (EN) (62.48 KB - PDF)

**First published:** 16/11/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-macimorelin-aeterna-zentaris_en.pdf)

#### News on Ghryvelin (previously Macimorelin Aeterna Zentaris)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018) 16/11/2018

#### More information on Ghryvelin (previously Macimorelin Aeterna Zentaris)

- [EMEA-001988-PIP01-16-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001988-pip01-16-m02)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/05/2024

## Share this page

[Back to top](#main-content)